Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $32
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $30 to $32.
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $30 to $32.